Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension

Drugs of Today

Volumn 46, Issue 5, 2010, Pages 339-350

  Ahrens, K ^a   Bramlage, P ^a  

^a Institut für Kardiovaskuläre Pharmakologie und Epidemiologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENDROFLUMETHIAZIDE; HYDROCHLOROTHIAZIDE; OLMESARTAN; PERINDOPRIL; POTASSIUM; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; ATHEROSCLEROSIS; BINDING AFFINITY; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; REVIEW; SYSTOLIC BLOOD PRESSURE;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; HYPERTENSION; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 77954704464     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.5.1469896     Document Type: Review

References (50)

1. Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., He, J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005, 365(9455): 217-23. (Pubitemid 40138015)
2. Mancia, G., Laurent, S., Agabiti-Rosei, E. et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens 2009, Epub ahead of print.
3. Mancia, G., De, B.G., Dominiczak, A. et al. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25(6): 1105-87.
4. Rosendorff, C., Black, H.R., Cannon, C.P. et al. Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007, 115(21): 2761-88.
5. Kaplan, N.M. Combination therapy for hypertension. Nat Rev Cardiol 2009, 6(4): 270-1.
6. Jamerson, K., Weber, M.A., Bakris, G.L. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359(23): 2417-28.
7. Benson, S.C., Pershadsingh, H.A., Ho, C.I. et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43(5): 993-1002.
8. Yusuf, S., Teo, K.K., Pogue, J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358(15): 1547-59.
9. Yusuf, S., Teo, K., Anderson, C. et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet 2008, 372(9644): 1174-83.
10. Cohn, J.N., Tognoni, G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345(23): 1667-75. (Pubitemid 33126822)
11. McMurray, J.J., Ostergren, J., Swedberg, K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003, 362(9386): 767-71.
12. Oparil, S., Kjeldsen, S.E., Hedner, T., Narkiewicz, K. ONTAR-GET, TRANSCEND and PROFESS-Clarifying, confusing or misleading? Blood Press 2009, 18(1-2): 4-6.
13. Rippin, J., Bain, S.C., Barnett, A.H. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. J Diabetes Complications 2002, 16(3): 195-200. (Pubitemid 34553326)
14. Nissen, S.E., Tuzcu, E.M., Libby, P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 2004, 292(18): 2217-25.
15. Wang, J.G., Li, Y., Franklin, S.S., Safar, M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: A quantitative overview. Hypertension 2007, 50(1): 181-8.
16. Leenen, F.H., Nwachuku, C.E., Black, H.R. et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006, 48(3): 374-84.
17. Dahlof, B., Sever, P.S., Poulter, N.R. et al. Prevention of cardiovascular events with on antihypertensive regimen of amlodipine adding Perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005, 366(9489): 895-906.
18. Law, M.R., Morris, J.K, Wald, N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338: bl665.
19. Faruqui, A.A. Evaluation of safety and efficacy of telmisartan-amlodipine combination in treating hypertension. J Indian Med Assoc 2008, 106(9): 612-4, 624.
20. Littlejohn, TW. 3rd, Majul, C.R., Olvera, R. et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009, 11(4): 207-13.
21. Littlejohn, T.W. 3rd, Majul, C.R., Olvera, R. et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: Results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4x4 factorial study. Postgrad Med 2009, 121(2): 5-14.
22. Negro, R., Hassan, H. The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. J Renin Angiotensin Aldosterone Syst 2006, 7(4): 243-6. (Pubitemid 46380776)
23. Sharma, A., Bagchi, A., Kinagi, S.B., Sharma, Y.K., Baliga, V.P., Bollmall, C. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther 2007, 29(12): 2667-76.
24. Jamerson, K.A., Bakris, C.L., Wun, C.C. et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004, 17(9): 793-801.
25. Oparil, S., Weber, M. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: An emerging strategy in hypertension therapy. Postgrad Med 2009, 121(2): 25-39.
26. Chobanian, A.V., Bakris, G.L., Black, H.R. et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003, 289(19): 2560-72.
27. Mason, R.P. A rationale for combination therapy in risk factor management: A mechanistic perspective. Am J Med 2005, (118, Suppl. 12A): 54-61.
28. Weir, M.R. Effects of renin-angiotensin system inhibition on end-organ protection: Can we do better? Clin Ther 2007, 29(9): 1803-24.
29. Coyle, J.D., Gardner, S.F., White, C.M. The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus. Ann Pharmacother 2004, 38(10): 1731-8.
30. Fogari, R., Derosa, G., Zoppi, A. et al. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens 2007, 20(4): 417-22.
31. Thone-Reineke, C,, Steckelings, U.M., Unger, T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl 2006, 24(1): S115-21.
32. Koshiyama, H., Tanaka, S., Minamikawa, J. Effect of calcium channel blocker amlodipine on the intimal-medial thickness of carotid arterial wall in type 2 diabetes. J Cardiovasc Pharmacol 1999, 33(6): 894-6.
33. Wang, J.G., Staessen, J.A., Li, Y. et al. Carotid intima-media thickness and antihypertensive treatment: A meta-analysis of randomized controlled trials. Stroke 2006, 37(7): 1933-40.
34. Klingbeil, A.U., Schneider, M., Martus, P., Messerli, F.H., Schmieder, R.E. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115(1): 41-6.
35. Neldam, S., Edwards, C. Long-term, open-label evaluation of the safety and efficacy of telmisartan 80 mg/hydrochlorothiazide 25 mg fixed-dose combination alone or with other antihypertensive medication. Expert Opin Pharmacother 2009, 10(3): 345-52.
36. Neutel, J.M., Klein, C., Meinicke, T.W., Schumacher, H. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002, 11(5): 302-9.
37. Fogari, R., Zoppi, A., Derosa, G. et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007, 21(3): 220-4.
38. Neldam, S., Edwards, C. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: Results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol 2006, 15(3): 151-60.
39. Rudd, P. Clinicians and patients with hypertension: Unsettled issues about compliance. Am Heart J 1995, 130(3, Pt. 1): 572-9.
40. Lacourciere, Y. A new fixed-dose combination for added blood pressure control: Telmisartan plus hydrochlorothiazide. J Int Med Res 2002, 30(4): 366-79. (Pubitemid 34993560)
41. Bramlage, P., Hasford, J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment - A review. Cardiovasc Diabetol 2009, 8: 18.
42. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991, 265(24): 3255-64.
43. Bramlage, P. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. Expert Opin Pharmacother 2009, 10(11): 1755-67.
44. Lind, L., Berne, C., Lithell, H. Prevalence of insulin resistance in essential hypertension. J Hypertens 1995, 13(12, Pt. 1): 1457-62. (Pubitemid 26015762)
45. Ersoy, C., Imamoglu, S., Budak, F., Tuncel, E., Erturk, E., Oral, B. Effect of amlodipine on insulin resistance and tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients. Indian J Med Res 2004, 120(5): 481-8.
46. Lender, D., Arauz-Pacheco, C., Breen, L., Mora-Mora, P., Ramirez, L.C., Raskin, P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999, 12(3): 298-303.
47. Kjeldsen, S.E., Jamerson, K.A., Bakris, G.L. et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH study. Blood Press 2008, 17(1): 7-17.
48. Wright, J.M., Musini, V.M. First-line drugs for hypertension. Cochrane Database Syst Rev 2009, (3): CD001841.
49. Eriksson, J.W., Jansson, P.A., Carlberg, B. et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: The mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension 2008, 52(6): 1030-7.
50. Schindler, C., Bramlage, P., Kirch, W., Ferrario, C.M. Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag 2007, 3(1): 125-37.